Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (February 2025)
15 slides from Enveric Biosciences's investor presentation, Feb 26, 2025
Slide 1: Next Generation Mental Health Corporate Presentation Q1 2025
yp Nasdaq:ENVB = ot ENVERIC ? fener tecin~ Bl"O BC ISB NUC E Ss CORPORATE PRESENTATION QI 2025 Enveric.com
Slide 2: Disclaimer
Disclaimer No Offer or Solicitation nicati ational purposes onl is not inte 1d does nstitute an offer means of a prospectus meeting the fsecuritie solicitation of an offer to securities or a solicitat requirements of Section 10 of the Securities A roval, It does not consti (ct of 1933, as amended, I
Slide 3: Slide 3
Slide 4: Significant Global Health Issues: Depression, Anxiety & PTSD
Significant Global Health Issues: Depression, Anxiety & PTSD 65 million in the US ey) 40% 1 billion globally Experience a neuropsychiatric First line SSRI treatments work disorder at some time in their lives for less than half of patients Recent Discovery: Mental health disorders are associated with
Slide 5: Neuroplastogens: A New Class of Drugs
Neuroplastogens: A New Class of Drugs Prefrontal Cortex Healthy Brain: Neurons in the prefrontal cortex (PFC) regulate emotional behavior via Top-Down control of the amygdala. Neuroplastogens stimulate Neuropsychiatric Illness: Reduced + . . a . . neuroplasticity in the PFC, which restores This modu
Slide 6: Psychedelic Neuroplastogen Drawbacks
Psychedelic Neuroplastogen Drawbacks: * Current psychedelic neuroplastogens in clinical trials cause hallucinations in the patient * Can require 8 hrs in-clinic treatment with two healthcare providers present, plus pre and post treatment counselling * Often require psychotherapy as part of the treat
Slide 7: EB-003: Non-Hallucinogenic, Orally Available, Neuroplastogenic DMT Analog
EB-003: Non-Hallucinogenic, Orally Available, Neuroplastogenic DMT Analog * Synthesized library of DMT analogs « Assessed preclinical properties * Invitrotarget engagement * Invivohead twitch response in mice * Invitroneuronal development * Invitroand in vivo pharmacokinetics * Invivoanxiolytic effi
Slide 8: EB-003: A New Treatment Standard
EB-003: A New Treatment Standard Approved Psychedelic rgeted Benefits” Antidepressants Neuroplastogens For EB-003 Immediate efficacy S Vv Low side effects VY Treatment in-clinic not required Vv v Large patient population Va Vv Induces neuroplasticity in brain v VY *To be proven in human clinical tri
Slide 9: EB-003: Development Underway
EB-003: Development Underway Synopsis of Target Benefits * Reduced hallucination profile, treatment in clinic not required + Lower side effects * Rapid acting * Orally bioavailable + Intended to be prescribed for regular maintenance and taken at times and in settings convenient to patient Ql qa | @
Slide 10: EVM401: Lead Discovery Underway
EVM40O1l: Lead Discovery Underway Overview + Novel phenylalkylamines and indolethylamines + Anticipated to interact with key brain receptors associated with mental health disorders and addiction. Potential Applications: + Early analysis suggests EVM401 compounds could target: + Substance use disorde
Slide 11: Market Potential: Redefining the Treatment Landscape for Mental Health Disorders
Market Potential: Redefining the Treatment Landscape for Mental Health Disorders Current Approved Predicted Neuroplastogen Antidepressant Market: EB-003: A Breakthrough Market: « Neuroplastogen Cs = Leading Neuroplastogen $35.4.8Billion ay Global market driven by the rising (-) EB-003 could be one o
Slide 12: Product Pipeline
Product Pipeline Discovery Preclinical IND Phase1 Partner / Licensee Available for Partnering Partner EB-003 & EVM301 Series railable Neuroplastogens EVM401 Series . Neuroplastogens Aveilete Out-Licensed Licensee eieHolee SVMEIO Spies MycoMedica Life Sciences Psilocin Prodrugs Topical Candidates for
Slide 13: Management
Management Management Team Joseph Tucker, Ph.D. Chief Executive Officer & Director Kevin Coveney, CPA Chief Financial Officer Peter Facchini, Ph.D. Chief Innovation Officer Jillian Hagel, Ph.D. Vice President Innovation Ja nasdaq:enve Board of Directors Michael D. Webb Board Chair George Kegler Dire
Slide 14: Potential First in Class Entrant to Large Mental Health Market
Potential First in Class Entrant to Large Mental Health Market EB-003: A Paradigm Shifting Drug Candidate * EB-003 is one of the leading neuroplastogen drug candidates + Anticipate filing IND in Q] of 2026 and Phase | start in Q2 2026 New Drug Class Market Opportunity + A $35.4 billion market awaits
Slide 15: Nasdaq: ENVB
Nasdag :ENVB ENVERITGMY fantortecin™ Mental Health™ BIOS CIENCES Enveric.com
Enveric Biosciences — Investor Presentation (February 2025) on 6ix